Two excellent candidates are Vertex Pharmaceuticals ( VRTX -1.05%) and Axsome Therapeutics ( AXSM -1.06%). Here's what makes ...

Axsome reported $122 million in Q1 net sales, driven by OVALITY and Sunosi. The company plans to launch Symbravo for acute migraine treatment next month. Positive Phase 3 trial results for ...

Payer coverage for SUNOSI across all channels is approximately 83% of all ... and 5-HT 1A agonist being developed for the treatment of attention deficit hyperactivity disorder (ADHD), major depressive ...

Sunosi’s net product sales were $25.2 million ... III studies for treating attention deficit hyperactivity disorder (ADHD) and MDD. The company announced top-line data from the phase III ...

Shifting now to our ongoing Phase III clinical development programs for Solriamfetol, which is being evaluated in ADHD, MDD ... in 2024 were $53.4 million. Sunosi net product revenues were ...

already marketed as SUNOSI for excessive daytime sleepiness, is being developed for multiple additional indications including ADHD, major depressive disorder with excessive daytime sleepiness, binge ...

Sunosi net product revenues were $25.2 million ... We've announced positive results in ADHD. And while you can't make cross-trial comparisons and you'll always be careful about that because ...

Payer coverage for SUNOSI across all channels is approximately ... for the treatment of attention deficit hyperactivity disorder (ADHD), major depressive disorder (MDD) with EDS, binge eating ...